http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010533723-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D333-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C311-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-381 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C303-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C303-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate | 2008-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2010533723-A |
| titleOfInvention | Inhibitor of β-amyloid formation |
| abstract | A novel sulfonamide compound useful for the treatment of conditions associated with β-amyloid production is described and its route of preparation is also described. This sulfonamide compound has the following structure, and R 4 to R 3 are defined in this specification. Also provided are pharmaceutical compositions containing such compounds and / or prodrugs of such compounds and physiologically compatible carriers. These compounds inhibit β-amyloid production, as well as Alzheimer's disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, Dutch hereditary amyloid cerebral hemorrhage, inclusion body myositis, mild cognitive impairment (MCI), and Down's syndrome It is particularly useful for treatment. [Chemical 1] |
| priorityDate | 2007-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 341.